Thyroid and renal disorder occurrences were correlated with anti-PD-1, and incidences of IRR, hepatobiliary disorders and pyrexia (or chills) were more correlated with anti-PD-L1 therapy. This evidence concerns the gene CD274 and thyroiditis.